Longer storage of red blood cells does not affect mortality in transfused liver transplant recipients by Kwon, Ji Hye et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Longer storage of red blood cells does not affect mortality in transfused liver
transplant recipients
Kwon, Ji Hye ; Han, Sangbin ; Cho, Duck ; Spahn, Donat R ; Ko, Justin S ; Kim, Do Yeon ; Jun, Joo
Hyun ; Gwak, Mi Sook ; Kim, Gaab Soo
Abstract: BACKGROUND: The characteristics of red blood cell (RBC) products change after 2 weeks
of cold storage. It is unclear whether older RBCs affect mortality after liver transplantation. This retro-
spective cohort study aimed to evaluate the association between the age of transfused RBCs and death
after living donor liver transplantation (LDLT). STUDY DESIGN AND METHODS: Of 200 recipients
who underwent LDLT, 118 who received RBCs with a mean storage duration of less than 10 days (shorter
storage group) were compared with 82 with an RBC mean storage duration of more than 14 days (longer
storage group). Key exclusion criteria were transfusion of very fresh RBCs stored for less than 4 days
and transfusion of old RBCs in recipients of the shorter storage group. The primary outcome was post-
transplant overall death. Survival analysis was performed using the Cox model. RESULTS: Mean RBC
storage duration was 7 days in the shorter storage group and 17 days in the longer storage group. Death
probability at 1, 2, and 5 years posttransplant was 5.1%, 7.6%, and 13.6% in the shorter storage group,
respectively, and 6.1%, 8.5%, and 13.5% in the longer storage group. Death risk was comparable between
the two groups in univariable (hazard ratio [HR] 1.00, 95% confidence interval [CI], 0.47-2.16, p = 0.991)
and multivariable (HR 1.07, 95% CI, 0.46-2.50, p = 0.882) analyses. Graft failure risk was also compa-
rable (HR 1.04, 95% CI, 0.50-2.18, p = 0.916). Hepatocellular carcinoma recurrence probability at 1, 2,
and 5 years was 10.8%, 15.4%, and 23.1%, respectively, in the shorter storage group and 11.4%, 15.9%,
and 20.7% in the longer storage group (HR 0.84, 95% CI, 0.37-1.89, p = 0.670). No significant differences
were observed regarding graft regeneration/function, vascular/biliary complications, acute kidney injury,
surgical site infection, or rejection (p > 0.05). CONCLUSIONS: No evidence was found that transfusion
of old RBCs contributes to death after LDLT.
DOI: https://doi.org/10.1111/trf.14961
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-159246
Journal Article
Accepted Version
Originally published at:
Kwon, Ji Hye; Han, Sangbin; Cho, Duck; Spahn, Donat R; Ko, Justin S; Kim, Do Yeon; Jun, Joo Hyun;
Gwak, Mi Sook; Kim, Gaab Soo (2018). Longer storage of red blood cells does not affect mortality in
transfused liver transplant recipients. Transfusion, 58(11):2529-2537.
DOI: https://doi.org/10.1111/trf.14961
1 
Longer storage of red blood cells does not affect mortality in transfused 1 
liver transplant recipients 2 
 3 
Ji Hye Kwon,1 Sangbin Han,1 Duck Cho, MD,2 Donat R. Spahn,3 Justin S. Ko,1 Do Yeon Kim,1  4 
Joo Hyun Jun,4 Mi Sook Gwak,1 and Gaab Soo Kim1 5 
 6 
1From the Department of Anesthesiology and Pain Medicine, Samsung Medical Center, 7 
Sungkyunkwan University School of Medicine, Seoul, Korea 8 
2From the Department of Laboratory Medicine and Genetics, Samsung Medical Center, 9 
Sungkyunkwan University School of Medicine, Seoul, Korea 10 
3From the Institute of Anesthesiology, University and University Hospital of Zürich, Zürich, 11 
Switzerland 12 
4From the Department of Anesthesiology and Pain Medicine, Kangnam Sacred Heart 13 
Hospital, Hallym University College of Medicine, Seoul, Korea 14 
 15 
Correspondence to (address reprint requests to): Han S, Department of Anesthesiology and 16 
Pain Medicine, Samsung Medical Center, Irwon-ro 81, Gangnam-gu, Seoul 06351, Korea. 17 
Tel.: +82-2-3410-2470; Fax: +82-2-3410-0361; E-mail: hans5@skku.edu 18 
 19 
Running head: Old RBC TF in Liver Transplantation 20 
Word counts: 250 (abstract), 3275 (main text) 21 
This paper includes 3 tables, 2 figures, 1 supplementary table, and 3 supplementary figures. 22 
 23 
 24 
2 
Key words: Cytokines; Erythrocyte Transfusion; Immunomodulation; Living Donors; 1 
Neoplasm Metastasis; Infection, Surgical Site; Leukocytes; Transplantation 2 
 3 
Conflicts of Interest and Source of Funding: The authors of this manuscript declare no 4 
conflict of interest. 5 
 6 
Funding source: Nothing to report. 7 
 8 
Ethics committee of the Samsung Medical Center, identifier SMC 2017-05-013.  9 
 10 
Authorship 11 
Ji Hye Kwon designed the study, collected data, analyzed data, and wrote the manuscript 12 
 E-mail: jh0828.kwon@samsung.com 13 
Sangbin Han designed the study, collected data, interpreted data, and wrote the manuscript 14 
 E-mail: sangbin.han@samsung.com 15 
Duck Cho interpreted data, gave statistical advice, and provided critical revisions 16 
 E-mail: duck.cho@samsung.com 17 
Donat R. Spahn interpreted data, gave statistical advice, and provided critical revisions 18 
 E-mail: donat.spahn@usz.ch 19 
Justin S. Ko collected data, analyzed data, and wrote the manuscript 20 
 E-mail: jsko@skku.edu 21 
Do Yeon Kim collected data, analyzed data, and wrote the manuscript 22 
 E-mail: doyeon31.kim@samsung.com 23 
Joo Hyun Jun collected data, analyzed data, and wrote the manuscript 24 
E-mail: ilpleut@naver.com 25 
3 
Mi Sook Gwak contributed to conception, interpreted data, and gave critical revision 1 
 E-mail: gwakms@skku.edu 2 
Gaab Soo Kim contributed to conception, acquisition of data, and interpretation of data 3 
 E-mail: gskim@skku.edu 4 
 5 
ABBREVIATIONS 6 
HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HR = hazard ratio; LDLT = living 7 
donor liver; RBC = red blood cell 8 
9 
4 
ABSTRACT 1 
BACKGROUND: The characteristics of red blood cell (RBC) product significantly change 2 
after 2 weeks of cold storage. It is unclear whether older RBCs affect mortality after liver 3 
transplantation. Thus, in this retrospective cohort study, we aimed to evaluate the association 4 
between the age of transfused RBCs and death after living donor liver transplantation (LDLT).  5 
STUDY DESIGN AND METHODS: Of 200 recipients who underwent LDLT, 118 who 6 
received RBCs with a mean storage duration of <10 days (shorter-storage group) were 7 
compared with 82 with a RBC mean storage duration of >14 days (longer-storage group). 8 
Key exclusion criteria were transfusion of very fresh RBCs stored for <4 days and 9 
transfusion of old RBCs in recipients of shorter-storage group. The primary outcome was 10 
post-transplant overall death. Survival analysis was performed using the Cox model.  11 
RESULTS: Mean RBC storage duration was 7 days in shorter-storage group and 17 days in 12 
longer-storage group. Death probability at 1/2/5 years post-transplant was 5.1%/7.6%/13.6% 13 
in shorter-storage group, respectively, and 6.1%/8.5%/13.5% in longer-storage group. Death 14 
risk was comparable between the two groups in univariable (hazard ratio [HR]=1.00 [0.47–15 
2.16], p=0.991) and multivariable (HR=1.07 [0.46–2.50], p=0.882) analyses. Graft failure 16 
risk was also comparable (HR=1.04 [0.50–2.18], p=0.916). Hepatocellular carcinoma 17 
recurrence probability at 1/2/5 years was 10.8%/15.4%/23.1%, respectively, in shorter-18 
storage group and 11.4%/15.9%/20.7% in longer-storage group (HR=0.84 [0.37–1.89], 19 
p=0.670). There were no significant differences regarding graft regeneration/function, 20 
vascular/biliary complications, acute kidney injury, surgical site infection, and rejection 21 
(p>0.05).  22 
CONCLUSIONS: We found no evidence that transfusion of old RBCs contributes to death 23 
after LDLT. 24 
5 
Despite continuing improvements in surgical and anesthetic techniques, the amount of blood 1 
lost during liver transplantation is significant. Consequently, allogeneic red blood cell (RBC) 2 
transfusion is sometimes inevitable to maintain a sufficient tissue oxygen supply and save 3 
lives. However, RBC transfusion is associated with various immunologic and 4 
nonimmunologic effects, and some of them are known to be fatal.1,2 Thus, various methods, 5 
such as blood salvage, leukoreduction, irradiation, and washing, are employed to prevent 6 
adverse effects of RBC transfusion in liver transplant recipients.2,3 7 
The use or nonuse of RBCs with certain storage durations can also be considered as a 8 
method to prevent adverse effects. However, this method should be considered carefully after 9 
weighing the expected clinical benefit against the potential for a shortage of RBC products.4,5 10 
Recently, we found that perioperative transfusion of fresh RBCs stored for <4 days was 11 
associated with increased mortality in immunosuppressed liver transplant recipients,6 being in 12 
line with recent evidences demonstrating the risk of blood stored for a short duration.7 On the 13 
other hand, the use of old RBCs also carries potential risks because the structure of the RBCs 14 
and the biochemical characteristics of the storage medium change significantly after 2 weeks 15 
of cold storage,8,9 a condition termed the "RBC storage lesion." Although such changes have 16 
been found to be associated with vasoconstriction, coagulation disturbance, inflammation, 17 
and immunomodulation,9 the clinical relevance of these changes remains unclear. Recent 18 
systematic reviews10-13 and four large trials have demonstrated no significant impact of old 19 
RBCs on mortality in the general hospital population,14 critically ill population,15,16 and 20 
cardiac surgical population.17 However, only a limited number of studies have been 21 
performed in liver transplant recipients, and the studies have reported conflicting results.18-20 22 
Therefore, we aimed to reappraise the risk of old RBCs in liver transplant recipients to 23 
determine whether there is a clinical benefit from avoiding use of such RBCs. 24 
 25 
6 
MATERIALS AND METHODS 1 
Subjects and data collection 2 
We initially screened the records of 480 patients who underwent their first adult-to-adult 3 
living donor liver transplantation between January 2006 and May 2014 in our hospital and 4 
received at least one RBC unit during the perioperative period, which was defined as the time 5 
during surgery and within 2 weeks after transplantation.6 Of these recipients, we excluded 6 
135 recipients who received at least one RBC unit stored for <4 days.6 Among the remaining 7 
358 recipients, 111 recipients who received RBCs with a mean storage duration of 10–14 8 
days were further excluded to increase the sensitivity of potential effects of older RBCs and 9 
decrease the risk of type II error by increasing the gap in RBC storage duration between study 10 
groups. Fourteen recipients who received RBCs with a mean storage duration of <10 days but 11 
who also received at least one RBC unit stored for >14 days were further excluded along with 12 
11 recipients who received at least one RBC unit prior to surgery during admission. Nine 13 
recipients who were confirmed via pathology to have hepatocellular carcinoma (HCC) 14 
macrovascular invasion were further excluded due to the very high risk of death from HCC 15 
recurrence.6,21 Among the remaining 200 recipients, 118 recipients who received RBCs with 16 
a mean storage duration of <10 days were included in shorter-storage group and 82 recipients 17 
who received RBCs with a mean storage duration of >14 days were included in longer-18 
storage group. No recipients died within 2 weeks of transplantation. Recipients were followed 19 
until death or the end of the study in September 2017 for a maximum of 5 years. All data 20 
were derived from our institution’s electronic medical records and prospectively collected 21 
liver transplantation database. The institutional review board (SMC 2017-05-013) approved 22 
this retrospective cohort study and waived the requirement for written informed consent. 23 
 24 
Operative management 25 
7 
Acceptance criteria for liver donation were ≤65 years, body mass index <35 kg/m2, 1 
macrosteatosis degree ≤30%, and residual liver volume ≥30%. All grafts consisted of 2 
segment 5–8 excluding the middle hepatic vein trunk. Graft implantation was performed 3 
using the piggyback technique. After portal vein anastomosis, the graft was reperfused by 4 
consecutively unclamping the hepatic vein and portal vein. Hepatic artery anastomosis was 5 
then performed, followed by biliary anastomosis. Immunosuppression was performed using 6 
methylprednisolone, basiliximab, and mycophenolate mofetil in addition to tacrolimus.21 7 
Tacrolimus treatment was initiated on postoperative day 3, with a trough plasma 8 
concentration of 10 ng/mL maintained during the first month and a concentration of 5–8 9 
ng/mL maintained thereafter. Hepatitis B virus (HBV) prophylaxis was performed using 10 
hepatitis B immunoglobulin (Green Cross Corp., Yongin, South Korea) until December 2007, 11 
and thereafter a combination of entecavir (0.5 mg/day) and hepatitis B immunoglobulin was 12 
used.21 A detailed description of liver donation and transplant criteria, surgical procedures, 13 
anesthetic management, immunosuppression, and HBV prophylaxis has been published 14 
previously.21,22 15 
 16 
RBC preparation 17 
RBCs were collected in bags containing citrate-phosphate-dextrose-adenine-1. Prior to 18 
transfusion, RBCs underwent post-storage leukoreduction using an RCM1 filter 19 
(Haemonetics, Braintree, MA) until March 2012, and thereafter RBCs underwent pre-storage 20 
leukoreduction using an RC2VAE filter (Haemonetics). Both filters reduce the number of 21 
residual leukocytes per RBC unit to <2105. All RBCs were further gamma-irradiated using 22 
our on-site cesium-137 irradiators: an IBL 437 (CIS, Bedford, MA) was used until February 23 
2008, and thereafter, a GammaCell 3000 was used (Best Theratronics, Ottawa, Ontario, 24 
Canada). The irradiation duration was modified based on dose distribution mapping 25 
8 
performed by outside experts so that the absorbed-dose at the center of the target was 25 Gy, 1 
with a minimum of >15 Gy and maximum of <50 Gy throughout the target (Supplementary 2 
Fig. S1). The use of RBCs stored for >24 hours after irradiation was prohibited because of 3 
concerns of massive RBC storage lesion (e.g. hyperkalemia) without the consideration of 4 
plasma washing.23 Compatibility was routinely evaluated using ABO/Rh typing, testing 5 
recipient serum for clinically important alloantibodies, and serologically cross-matching 6 
donor RBCs with recipient serum. Our blood bank delivered RBCs to the operating room 7 
using the first-in-first-out principle to consume older RBCs before newer one.6 8 
 9 
Transfusion policy 10 
The transfusion policy of our transplant team is characterized by restrictive and prophylactic 11 
use of blood products.3,6,22 Each blood component was separately transfused based on its 12 
respective indication. The trigger for allogeneic RBC transfusion was hemoglobin 8.0 g/dL. 13 
Blood salvage was routinely used for autologous RBC transfusion, with salvaged RBCs being 14 
used first when RBC transfusion was indicated. A leukocyte depletion filter was routinely 15 
used before autotransfusion for HCC patients.3 Use of fresh frozen plasma was indicated 16 
when the prothrombin time international normalized ratio was >3.0. Platelet transfusion was 17 
indicated when the platelet count decreased to <30×109/L. Cryoprecipitate was indicated 18 
when the fibrinogen level was <80 mg/dL. Korean national policy limits storage of RBCs, 19 
platelets, fresh frozen plasma, and cryoprecipitate to 35 days, 5 days, 1 year, and 1 year, 20 
respectively. The RBCs, platelets, fresh frozen plasma, and cryoprecipitate were stored at 1–6, 21 
22–26, <-20, and <-20˚C, respectively. 22 
 23 
Variables and statistical analyses 24 
The primary outcome was post-transplant death. Survival analyses were performed using the 25 
9 
Cox model, and the results are described using hazard ratio (HR) and 95% confidence 1 
interval. The backward selection process was performed for all variables evaluated during the 2 
univariable analyses to generate a multivariable model, using p < 0.05 for the inclusion of 3 
variables and p > 0.10 for the removal of variables. The secondary outcomes were graft 4 
failure, HCC recurrence, and clinical complications. Graft failure was defined as death or 5 
retransplantation. In terms of HCC recurrence, survival analysis was performed using the 6 
Fine and Gray model, instead of the Cox model, to account for the competing risk of HCC-7 
unrelated death because HCC-unrelated death significantly affects HCC recurrence 8 
probability in liver transplant recipients.21,24 Post-transplant complications were graded based 9 
on the modified Clavien-Dindo classification.25 The degree of graft regeneration was 10 
calculated from the graft volume derived from computed tomography and graft weight 11 
directly measured after the graft was procured.22 Exploratory analysis was performed 12 
following inclusion of the 41 recipients who met the inclusion criteria but were excluded 13 
because of mean RBC storage duration of 10-14 days. The continuous variables are 14 
summarized as median (25th percentile, 75th percentile). The categorical variables are 15 
presented as number (%) and analyzed using the chi-square test or Fisher's exact test. All 16 
reported p values are two-sided, and a p < 0.05 was considered to indicate a statistically 17 
significant result. Statistical analyses were performed using SPSS 20.0 (SPSS Inc., Chicago, 18 
IL, USA) or R 3.0.2 (R Development Core Team, Vienna, Austria; http://www.R-project.org/). 19 
 20 
RESULTS 21 
 22 
Among the 1,349 RBC units transfused into the 200 recipients during the 2-week period, 832 23 
units were stored for 4–10 days, and 517 units were stored for >14 days (Fig. 1). Mean RBC 24 
10 
storage duration was 7 (6–8) days in shorter-storage group and 17 (15–19) days in longer-1 
storage group. The number of transfused RBC units did not differ significantly between the 2 
two groups (6 [2–8] units in shorter-storage group vs. 6 [4–10] units in longer-storage group, 3 
p = 0.066). The sum of the storage duration of all transfused RBCs was 40 (19–58) unit-days 4 
in shorter-storage group and 110 (62–175) unit-days in longer-storage group (p < 0.001). 5 
There was a significant difference in recipient ABO blood type (p < 0.001): the proportions 6 
of A type (27.1% vs. 7.3%) and O type (40.7% vs. 32.9%) were higher in shorter-storage 7 
group, while the proportions of B type (25.4% vs. 41.5%) and AB type (6.8% vs. 18.5%) 8 
were higher in longer-storage group. The proportion of recipients who underwent 9 
transplantation during the post-storage leukoreduction period (the earlier period) was 10 
significantly greater in shorter-storage group, indicating that RBC storage duration increased 11 
over time in relation to increased blood stock in our hospital blood bank:5 mean storage 12 
duration of RBCs was 9 (7–14) days during the post-storage leukoreduction period and 15 13 
(12–19) days during the pre-storage leukoreduction period. As shown in Table 1, there were 14 
no significant differences between the two groups regarding donor/recipient age, 15 
donor/recipient gender, macrosteatosis, graft-to-recipient weight ratio, graft ischemia time, 16 
donor-recipient ABO blood type compatibility, body mass index, etiology of liver disease, 17 
model for end-stage liver disease score, HCC, platelet count, ascites, encephalopathy, or 18 
hepatorenal syndrome (p > 0.05). Operation time was longer by 31 minutes in longer-storage 19 
group (578 vs. 547 minutes, p = 0.010). The incidence of intraoperative abrupt massive 20 
bleeding was comparable (p > 0.99). The amounts of transfused fresh frozen plasma, platelet 21 
concentrates, and cryoprecipitate did not differ significantly between the two groups (p > 22 
0.05). 23 
After a median follow-up of 60 months, 27 recipients (13.5%) had died. The continuous 24 
value of mean RBC storage duration was not associated with death risk (HR=1.01 [0.94–25 
11 
1.08], p = 0.844). As shown in Fig. 2A, death probability at 1, 2, and 5 years after 1 
transplantation was 5.1% (1.0–9.0%), 7.6% (2.7–12.3%), and 13.6% (7.2–19.6%), 2 
respectively, in shorter-storage group and 6.1% (0.8–11.1%), 8.5% (2.3–14.4%), and 13.5% 3 
(5.7–20.6%), respectively, in longer-storage group. Death risk was comparable between the 4 
two groups (HR=1.00 [0.47–2.16], p = 0.991). The presence of HCC beyond the Milan 5 
criteria was also associated with death risk (HR=3.90 [1.51–10.06], p = 0.005, 6 
Supplementary Table S1). As shown in Table 2, the multivariable analysis confirmed the lack 7 
of a significant difference in death risk between shorter-storage and longer-storage groups 8 
(HR=1.07 [0.46–2.50], p = 0.882). Only one recipient in each group underwent 9 
retransplantation, and accordingly, graft failure risk was also comparable between the two 10 
groups (HR=1.04 [0.50–2.18], p = 0.916, Fig. 2B). Within the subgroup of 109 recipients 11 
who were confirmed via pathology to have HCC, tumor recurrence probability at 1, 2, and 5 12 
years was 10.8% (3.2–18.47%), 15.4% (6.5–24.2%), and 23.1% (12.7–33.4%), respectively, 13 
in shorter-storage group and 11.4% (1.9–20.9%), 15.9% (5.0–6.9%) , and 20.7% (8.5–33.0%), 14 
respectively, in longer-storage group, respectively. Recurrence risk did not differ significantly 15 
between the two groups (HR=0.84 [0.37–1.89], p = 0.670, Fig. 2C). As shown in Table 3, 16 
there were no significant differences in early graft regeneration, early graft function, high-17 
grade complications, hepatic vascular complications, biliary complications, acute kidney 18 
injury, surgical site infection, or graft rejection (p > 0.05) between the two groups.  19 
After including 41 recipients who were excluded due to borderline mean RBC storage 20 
duration (10–14 days), death risk was comparable between shorter-storage group, borderline 21 
storage group, and longer-storage group (p = 0.894), indicating selection bias because of the 22 
exclusion of recipients with mean RBC storage duration of 10–14 days was not significant 23 
(Supplementary Fig. S2A). In addition, 241 recipients were stratified into four groups based 24 
on RBC storage quartile strata (4–7 days, n=59; >7 days and ≤10 days, n=66; >10 days and 25 
12 
≤16 days, n=68; and >16 days, n=48). The mean storage duration of each group was 6 (5–7), 1 
9 (8–9), 14 (11–15), and 19 (18–21) days, respectively. Compared to the shortest group, the 2 
other groups did not exhibit a significantly different risk in death (p = 0.614). Furthermore, 3 
there was no difference in death risk between the longest and shortest storage quartile (HR= 4 
1.5 [0.5–4.2], p = 0.423; Supplementary Fig. S2B). 5 
 6 
DISCUSSION 7 
 8 
The safety of transfusing old RBCs has long been controversial,10-12 and conflicting results 9 
have been observed in liver transplant recipients.18-20 In this study, we found no evidence that 10 
RBCs stored for a longer time contribute to post-transplant death. Death risk was essentially 11 
identical irrespective of the age of RBCs when mean storage duration was treated as a 12 
continuous (p = 0.844), dichotomous (p = 0.991), and quartile (p = 0.614) variable. 13 
Furthermore, RBC storage duration had no significant effect on graft failure, HCC 14 
recurrence, or clinical complications. Our findings are important because practical changes 15 
aimed at avoiding use of RBCs stored for longer periods of time is rational only if this 16 
practice improves post-transplant clinical courses because such avoidance can increase the 17 
potential for a shortage of RBC products. While it is generally accepted that perioperative 18 
RBC transfusion negatively affects recipient survival,26,27 the results from the current study 19 
suggest that the use of old RBCs is not a component of that negative impact. Thus, avoiding 20 
old RBCs may not decrease post-transplant death following perioperative transfusion. Future 21 
validation of our findings is important, along with continuous efforts to distinguish the real 22 
components underlying the negative impact of RBC transfusion on liver transplantat 23 
recipients. 24 
Because leukocytes and platelets as well as cell-derived free DNA and microvesicles 25 
13 
various cytokines, antibodies, and electrolytes in plasma are simultaneously infused together 1 
with RBCs, unwanted effects of RBC transfusion may be observed.7 The number and 2 
property of cells and molecules contained in RBC unit differ by various pre-transplant factors 3 
such as blood modification and storage duration.2,7 With respect to these issues, our study 4 
model presented advantages for the robustness of our data. Leukoreduction and irradiation 5 
were mandatory.2 A uniform irradiation dose was applied to our samples, and irradiator 6 
quality assurance was performed by external experts.28 Therefore, in our data, allogeneic 7 
leukocyte-related effects were unlikely to raise a significant bias. The timing of irradiation is 8 
another issue to be considered because elevated potassium levels in RBC unit stored for long 9 
periods following irradiation can lead a deleterious impact on reperfused graft.29,30 In this 10 
regard, the use of RBC units stored for >24 hours after irradiation were prohibited. 11 
Furthermore, we excluded RBC units stored for <4 days because these units were determined 12 
to significantly increase the risk of post-transplant mortality based on our liver transplant 13 
database.6 Although the underlying mechanisms are now under active investigation, negative 14 
impact of fresh RBCs may be associated with higher level of extracelllular free DNA and 15 
microvesicles in blood stored for a short duration,7 in addition to more viable leukocytes.31,32  16 
Of note, the association between the use of older RBCs and post-transplant mortality 17 
significantly changed after including fresh RBCs stored for <4 days (Supplementary Fig. S3), 18 
indicating the ease with which results can be distorted by a key pre-transfusion parameter. 19 
Finally, an alloantibody test was routine for these units, ruling out the presence of an 20 
alloimmunization-related event. This issue is particularly relevant for this population, because 21 
liver transplant recipients tend to receive multiple RBC units at multiple times.  22 
Donated RBCs can be stored for as long as 42 days before transfusion, based on the 23 
survival of one-quarter of the transfused RBCs during 1 day after transfusion;2,12 however, 24 
one concern is the uncertainty of clinically significant impacts of transfusing older RBCs 25 
14 
stored for different durations within the 42-day allowed time frame. Although conflicting 1 
results have been published on this issue, recent systematic reviews concluded that no 2 
definitive evidence supports the inferiority of older RBCs.10-12 Thereafter, the most recent 3 
meta-analysis evaluated two new large trials and 10 small previous trials with the shorter-4 
storage group including RBCs stored from 1.6–12.1 days, the longer-storage group including 5 
RBCs stored from 9.0–28.3 days, and the gap in RBC storage duration between groups 6 
ranging from 7.4–22.5 days, respectively, in mean (or median). This meta-analysis found a 7 
consistent lack of significant effects of RBCs with longer storage durations on key outcomes, 8 
particularly mortality, concluding that there is no support for avoiding older RBCs.13 After 9 
this meta-analysis, a large, multicenter, randomized trial of patients in the general hospital 10 
population demonstrated a lack of significant difference in in-hospital mortality between 11 
6,936 patients with a mean RBC storage duration of 13.0 days and 13,922 patient with a 12 
mean RBC storage duration of 23.6 days (odds ratio=1.05 [0.95–1.16], p = 0.34).14 In the 13 
most recent multicenter trial of critically ill patients, there was no significant difference in 90-14 
day mortality between 2,457 patients with a mean RBC storage duration of 11.8 days and 15 
2,462 patients with a mean RBC storage duration of 22.4 days.16 In liver transplant recipients, 16 
however, only three single-center retrospective studies have evaluated the association 17 
between older RBCs and post-transplant mortality.18-20 Although all of these studies used the 18 
same cutoff value for old RBCs (2 weeks), the results were different. Unfortunately, neither 19 
of the papers specified detailed RBC preparation processes or transfusion practices and only 20 
took into account the number of RBC units. Therefore, whether these findings were affected 21 
by other transfusion-related factors remains opaque. 22 
Various factors of inventory management may explain the significant difference in RBC 23 
storage duration among recipients with different ABO blood types, and these factors may 24 
include the age of RBCs at receipt, stock reserve, restock interval, consistent or episodic 25 
15 
transfusion demand, and variance in inventory turnover.5 That is, higher institutional demand-1 
to-reserve ratio in type O and A may have been involved. Although higher demand may 2 
cause a shortage of RBC products, there were no cases in which ABO-compatile RBCs were 3 
not available. Results of univariable analysis indicated that ABO blood type was not a 4 
significant factor associated with post-transplant death in our study (p = 0.635). 5 
This study has several limitations. First, as a retrospective study, we could not exclude the 6 
possibility of bias from unobserved (unmeasured or unmeasurable) variables. Nonetheless, 7 
rigorous patient selection, uniformly applied blood preparation, and transfusion practices 8 
strictly based on institutional protocols along with standardized anesthetic and surgical 9 
management helped to minimize the risk for bias. Second, RBCs can be stored for as long as 10 
35 days in South Korea; thus, the impact of RBCs stored for >35 days were not evaluated, 11 
even though previous studies reported conflicting results regarding this issue.33-35 On the 12 
other hand, our study had advantages as well. Because the mean RBC storagd duration for the 13 
control group (shorter-storage group) was only 7 days, the cells were fresher than those in 14 
many previous studies that reported mean RBC storage duration of close to 14 days, a time 15 
point when RBC storage lesion is thought to already be significant. 16 
In summary, the risk of post-transplant death, in addition to graft failure, HCC recurrence, 17 
and major clinical complications, was not significantly associated with the storage duration of 18 
RBCs transfused during the perioperative period. Despite the methodological limitations, our 19 
findings suggest that there is no need to change RBC transfusion practices to avoid RBCs 20 
stored for longer durations or limit transfusion to fresher RBCs for liver transplant recipients.  21 
  22 
23 
16 
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FIGURE LEGENDS 1 
 2 
Fig. 1. Histogram of storage duration of transfused red blood cells (RBCs) for 118 recipients 3 
in shorter-storage group (gray) and 82 recipients in longer-storage group (black). 4 
 5 
Fig. 2. Comparison of post-transplant (A) overall survival, (B) graft survival, and (C) 6 
hepatocellular carcinoma (HCC) recurrence. 7 
 8 
9 
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TABLE 1. Demographic and clinical characteristics of the patients 1 
 Shorter-storage group 
(n=118) 
Longer-storage group 
(n=82) 
p 
Graft factors    
Donor age (years) 31 (24-41) 33 (25-47) 0.106 
Male donor 113 (67.3) 67 (72.8) 0.353 
Blood-unrelated donor 26 (22.0) 23 (28.0) 0.331 
Macrosteatsis > 5% 88 (52.4) 44 (47.8) 0.482 
Graft-to-recipient weight ratio (%) 1.04 (0.89-1.24) 1.01 (0.89-1.22) 0.725 
ABO blood type incompatible graft 16 (9.5) 16 (17.4) 0.065 
Graft ischemia time (minutes) 117 (99-137) 118 (98-138) 0.779 
Hepatic inflow occlusion   0.417 
  0 92 (54.8) 46 (50.0)  
  1-2 34 (20.2) 16 (17.4)  
  ≥ 3 42 (25.0) 30 (32.6)  
Recipient factors    
Age (years) 53 (47-57) 53 (47-57) 0.854 
Male 129 (76.8) 74 (80.4) 0.496 
ABO blood type   <0.001 
  A 32 (27.1) 6 (7.3)  
  O 48 (40.7) 27 (32.9)  
  B 30 (25.4) 34 (41.5)  
  AB 8 (6.8) 15 (18.3)  
Body mass index (kg/m2) 24.2 (22.3-26.2) 23.8 (21.4-26.3) 0.494 
Hypertension 13 (7.7) 11 (12.0) 0.261 
Diabetes 60 (35.7) 29 (31.5) 0.496 
Time period*   <0.001 
2006-2007 17 (14.4) 5 (6.1)  
2008-2012 92 (78.0) 47 (57.3)  
  2012-2014 9 (7.6) 30 (36.6)  
Non-viral etiology 33 (19.6) 22 (23.9) 0.420 
Hepatocellular carcinoma   0.720 
  None 77 (45.8) 44 (47.8)  
  Within the Milan criteria 59 (35.1) 28 (30.4)  
  Beyond the Milan criteria 32 (19.0) 20 (21.7)  
MELD score 15 (12-23) 14 (10-21) 0.099 
Platelet count (109/L) 64 (46-92) 61 (44-104) 0.956 
Neutrophil-to-lymphocyte ratio 2.44 (1.67-4.58) 2.14 (1.44-3.64) 0.137 
Refractory ascites 40 (23.8) 21 (22.8) 0.858 
Hepatic encephalopathy   0.117 
  None 132 (78.6) 81 (88.0)  
  Grade I-III 28 (16.7) 7 (7.6)  
  Grade IV 8 (4.8) 4 (4.3)  
Hepatorenal syndrome 9 (7.6) 2 (2.4) 0.205 
Transplant factors    
Operative time (minutes) 547 (490-607) 578 (518-639) 0.010 
Abrupt massive bleeding events† 6 (9.8) 6 (9.4) >0.99 
Salvaged autologous RBCs (mL) 905 (651-1552) 987 (661-1477) 0.690 
Infused autologous RBCs (mL) 816 (456-1550) 828 (299-1312) 0.572 
Amount of perioperative transfusion    
  RBCs (units) 6 (2-8) 6 (4-10) 0.066 
  Fresh frozen plasma (units) 4 (2-7) 4 (2-8) 0.919 
  Platelets (units)‡ 8 (0-16) 6 (0-14) 0.515 
21 
  Cryoprecipitate (units) 6 (0-8) 4 (0-6) 0.500 
Tacrolimus concentration >10 ng/mL 75 (44.6) 40 (43.5) 0.857 
Data are presented as median (25th percentile, 75th percentile) or frequency (%). RBC, red blood cell.  1 
*2006–2007 represents post-storage leukoreduction and hepatitis B virus mono-prophylaxis. 2008–2 
2012 represents post-storage leukoreduction and hepatitis B virus dual-prophylaxis. 2012–2014 3 
represents pre-storage leukoreduction and hepatitis B virus dual-prophylaxis. †Analysis was 4 
performed within the subgroup of 125 patients who underwent surgery after May 2009, when data on 5 
abrupt massive bleeding began being recorded in the anesthetic chart. ‡One unit of single donor 6 
platelet was counted as 6 platelet units. 7 
8 
22 
TABLE 2. Multivariable analysis with post-transplant death as the dependent variable 1 
 HR (95% CI) p 
Longer-storage group 1.07 (0.46-2.50) 0.882 
Amount of RBC transfusion (units) 1.02 (0.96-1.08) 0.564 
Post-storage leukoreduction era (vs. pre-storage) 1.83 (0.56-6.04) 0.319 
Male donor 2.72 (0.94-7.90) 0.066 
Diabetes 2.07 (0.94-4.56) 0.070 
Platelet count (109/L) 1.01 (1.00-1.02) 0.008 
Hepatocellular carcinoma   
  Within the Milan criteria (vs. none) 2.25 (0.77-6.62) 0.140 
  Beyond the Milan criteria (vs. none) 5.06 (1.87-13.74) 0.001 
Operative time (minutes) 1.01 (1.00-1.01) 0.012 
Backward stepwise selection method was used for generating multivariable model. Infused 2 
autologous red blood cell (RBC) amount was not included in the selection process because it is highly 3 
similar to salvaged autologous RBC amount. Intraoperative abrupt massive bleeding event was not 4 
included in the selection process due to incomplete data (only available in 125 recipients who 5 
underwent surgery after May 2009, when the data on abrupt massive bleeding began being recorded in 6 
the anesthetic chart). RBC storage duration, perioperative RBC transfusion amount, and 7 
leukoreduction method were forced into the multivariable model. 8 
 9 
10 
23 
TABLE 3. Postoperative complications, according to the storage duration of red blood 1 
cells 2 
 
Shorter-storage 
group 
(n=118) 
Longer-storage 
group 
(n=82) 
p 
Primary graft non-function 0 0 - 
Graft regeneration for 2 weeks (%) 48 (34-67) 52 (39-73) 0.293 
AST at postoperative week 2 (IU/l) 41 (27-69) 35 (23-65) 0.196 
ALT at postoperative week 2 (IU/l) 157 (87-280) 139 (66-302) 0.592 
Prothrombin time at postoperative week 2 (INR) 1.14 (1.06-1.25) 1.16 (1.06-1.27) 0.990 
Total bilirubin at postoperative week 2 (mg/dL) 1.4 (1.0-2.1) 1.3 (0.9-2.2) 0.517 
Complication III-V 65 (55.1) 50 (61.0) 0.407 
  Grade IIIb-V 29 (24.6) 27 (32.9) 0.230 
Biliary complication (stricture or leakage) 46 (39.0) 36 (43.9) 0.487 
Hepatic vascular complication (stricture or 
thrombosis) 
10 (8.5) 9 (11.0) 0.553 
Acute kidney injury 48 (40.7) 36 (43.9) 0.650 
  Grade II to III 14 (11.9) 9 (11.0) 0.846 
Surgical site bleeding 6 (5.1) 9 (11.0) 0.120 
Surgical site infection 5 (4.2) 4 (4.9) >0.99 
Graft rejection 10 (8.5) 10 (12.2) 0.388 
Data are presented as median (25th percentile, 75th percentile) or frequency (%). AST, aspartate 3 
transaminase; ALT, alanine transaminase. 4 
 5 
 6 
24 
1 
25 
1 
26 
1 
27 
1 
28 
 1 
